Navigation Links
Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
Date:8/4/2011

CRANBURY, N.J., Aug. 4, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity. AZD2820 is a clinical candidate selected by AstraZeneca from its collaborative research program with Palatin Technologies.

Obesity is a global problem, with the World Health Organization estimating that over 1.5 billion adults are overweight and over 500 million are obese. Worldwide obesity has more than doubled since 1980.  A number of different metabolic and hormonal pathways are being evaluated by companies around the world in efforts to develop better treatments for obesity. Scientific research has established that melanocortin receptors have a role in eating behavior and energy homeostasis, and that some melanocortin receptor agonists decrease food intake and induce weight loss in animal studies.

The single center study is expected to enroll 90 subjects in a randomized, single-blind, placebo-controlled, Phase 1 trial in healthy male volunteers. For more information on this clinical trial with AZD2820, please visit www.clinicaltrials.gov .

"We are very pleased that AstraZeneca has initiated a Phase 1 clinical trial with a collaboration compound, demonstrating AstraZeneca's ongoing commitment and diligence in exploring melanocortin compounds for the treatment of obesity," said Dr. Carl Spana, President and Chief Executive Officer of Palatin.

Pursuant to the terms of the research collaboration and license agreement with AstraZeneca, Palatin is eligible for milestone payments upon achieving development and regulatory milestones and further payments on achievement of sales targets, in addition to roy
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
2. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
3. Palatin Technologies, Inc. Announces Results of Annual Stockholders Meeting
4. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
5. Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants
7. Palatin Technologies, Inc. December 31, 2010 Quarter Results; Teleconference and Webcast to be Held on February 24, 2011
8. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2011 Results
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
10. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
11. Palatin Announces Strategic Realignment of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... 2015 , ... There’s a new treatment option for excessive menstrual bleeding – ... FDA approved system in the last 14 years, and the only endometrial ablation product ... rate of 66%, the high Patient Satisfaction rate of 98%, and the fastest procedure ...
(Date:8/28/2015)... ... August 28, 2015 , ... Proove Biosciences , a ... International Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). The ASM ... a focus on evidence-based research and clinical application, the event gathered industry thought ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... for venture capital funds, investment firms and animal health companies to hear from ... raised $160 million. Several have also received licensing agreements or distribution contracts. ...
(Date:8/27/2015)... PARK, Calif. , Aug. 27, 2015  Asterias ... in the emerging field of regenerative medicine, today announced ... investor conferences in the month of September.  ... will present at Rodman & Renshaw,s 17th Annual Global ... ET/7:25am PT at the St. Regis Hotel in ...
Breaking Biology Technology:U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2
... with Innovative Technology for the Minimally Invasive Treatment ... Mark Approval PathwayEAST PROVIDENCE, R.I., Feb. 23 ... the innovative IlluminOss(TM) Photodynamic Bone Stabilization System for ... an ISO 13485 Certificate of Registration issued by ...
... Schering-Plough Corporation (NYSE: SGP ) ... human vaccine business unit, and the World Health ... vaccine manufacturing technology to developing countries.Fred Hassan, chairman ... commitment to innovation and to providing access to ...
... 23 Environmental Tectonics Corporation (Amex: ETC ... BioMedical Division,s Hyperbaric Chambers are equipped to satisfy the ... speech at George Mason University on January ... the quality of our health care while lowering its ...
Cached Biology Technology:IlluminOss Medical Receives ISO 13485 Certification 2Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries 2Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries 3Environmental Tectonics Corporation's BioMedical Division's Hyperbaric Chambers Address U.S. President Obama's Initiative to Computerize Medical Records 2Environmental Tectonics Corporation's BioMedical Division's Hyperbaric Chambers Address U.S. President Obama's Initiative to Computerize Medical Records 3Environmental Tectonics Corporation's BioMedical Division's Hyperbaric Chambers Address U.S. President Obama's Initiative to Computerize Medical Records 4
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/10/2015)... TELTOW, Germany , August 10, 2015 ... a world leader in Eye Tracking Technology for more ... OEM Eye Tracking Platform for integration into all consumer ... reference designs for seamless integration of eye tracking into ... HMDs and augmented reality smart glasses. Omnivision,s leading sensor ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... University Hospitals Case Medical Center hope to improve treatment ... providing doctors an unprecedented look at the stents they ... received a $1.7 million grant from the National Institutes ... primary investigators leading the effort are: David Wilson, professor ...
... monitoring using somatosensory evoked potentials has been ... injury. Previous studies only reported the ... mechanical factors-caused spinal cord injury. However, spinal ... mechanical factors, biochemical factors and vascular factors ...
... especially as the brown marmorated stink bugs spreads throughout the ... Podisus nigrispinus (Dallas), a predatory stink bug that is ... of cotton, soybean, tomato, corn, kale, and other crops. ... Entomological Society of America called "Effect of Egg Rearing ...
Cached Biology News:Imaging technology to improve survival of ischemic disease patients 2Imaging technology to improve survival of ischemic disease patients 3New study may aid rearing of stink bugs for biological control 2